Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics (SLNO)
:SLNO
RESEARCH TOOLSreports
Holding SLNO?
Track your performance easily
SLNO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$36.61 - $60.92
Previous CloseN/A
Volume118.06K
Average Volume (3M)586.78K
Market Cap
$2.02B
Enterprise Value$1.86B
Total Cash (Recent Filing)$2.73M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Mar 25, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.31
Shares Outstanding43,117,430
10 Day Avg. Volume493,057
30 Day Avg. Volume586,782
Standard Deviation0.70
R-Squared0.01
Alpha0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-14.67
Forecast
1Y Price Target
$74.83Price Target Upside59.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Soleno Therapeutics News
PremiumCompany Announcements
Soleno Therapeutics Reports Q3 Progress and Financials
PremiumPre-Earnings
Is SLNO a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Clinical Data And TrialsSoleno's lead drug candidate, DCCR, is viewed as eminently approvable with strong clinical data demonstrating tangible patient benefit in Prader-Willi syndrome.
Financial PositionAs of September 30, Soleno had cash, equivalents, and marketable securities of $284.7M, indicating a strong financial position.
Regulatory ApprovalA 90% probability of regulatory approval is ascribed to Soleno's lead drug candidate, DCCR, which is under review at the FDA.
Bears Say
Financial PerformanceSoleno reported a net loss of $1.83 per share, driven by substantially higher-than-expected operating expenses.
Obligations And ExpensesThe company is obligated to make cash payments up to $21.2M to former Essentialis stockholders upon achieving certain commercial milestones.
Regulatory And Market RisksRisks include failure to secure regulatory approval of DCCR in the U.S. for Prader-Willi syndrome, and slower-than-anticipated U.S. market uptake of DCCR due to market access or reimbursement issues.
---
Ownership Overview
17.69% Insiders
12.95% Mutual Funds
0.09% Other Institutional Investors
60.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLNO FAQ
What was Soleno Therapeutics’s price range in the past 12 months?
Soleno Therapeutics lowest stock price was $36.61 and its highest was $60.92 in the past 12 months.
What is Soleno Therapeutics’s market cap?
Soleno Therapeutics’s market cap is $2.02B.
When is Soleno Therapeutics’s upcoming earnings report date?
Soleno Therapeutics’s upcoming earnings report date is Mar 25, 2025 which is in 61 days.
How were Soleno Therapeutics’s earnings last quarter?
Soleno Therapeutics released its earnings results on Nov 06, 2024. The company reported -$1.83 earnings per share for the quarter, missing the consensus estimate of -$0.605 by -$1.225.
Is Soleno Therapeutics overvalued?
According to Wall Street analysts Soleno Therapeutics’s price is currently Undervalued.
Does Soleno Therapeutics pay dividends?
Soleno Therapeutics does not currently pay dividends.
What is Soleno Therapeutics’s EPS estimate?
Soleno Therapeutics’s EPS estimate is -1.06.
How many shares outstanding does Soleno Therapeutics have?
Soleno Therapeutics has 43,117,430 shares outstanding.
What happened to Soleno Therapeutics’s price movement after its last earnings report?
Soleno Therapeutics reported an EPS of -$1.83 in its last earnings report, missing expectations of -$0.605. Following the earnings report the stock price went up 0.44%.
Which hedge fund is a major shareholder of Soleno Therapeutics?
Currently, no hedge funds are holding shares in SLNO
---
Soleno Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.83 (59.62% Upside)
$74.83 (59.62% Upside)
Blogger Sentiment
Neutral
SLNO Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 165.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.36%
12-Months-Change
Fundamentals
Return on Equity
-49.55%
Trailing 12-Months
Asset Growth
366.90%
Trailing 12-Months
Company Description
Soleno Therapeutics
Soleno Therapeutics (SLNO) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's primary product candidate is DCCR (diazoxide choline) extended-release tablets, which is being developed for the treatment of Prader-Willi Syndrome (PWS), a complex genetic disorder characterized by insatiable appetite, obesity, and developmental issues. Soleno Therapeutics operates within the pharmaceutical sector, concentrating on addressing unmet medical needs in the field of rare diseases.
---
SLNO Stock 12 Month Forecast
Average Price Target
$74.83
▲(59.62% Upside)
Technical Analysis
Best Analysts Covering SLNO
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
+153.40%
assigned a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +153.40% per trade.
---